Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.0300 (-1.47%) ($4.0300 - $4.0300) on Thu. Apr. 14, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.48% (three month average) | RSI | 45 | Latest Price | $4.0300(-1.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2.1% a day on average for past five trading days. | Weekly Trend | AUTL declines -0.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(75%) IBB(71%) PAVE(60%) IBUY(57%) INDA(56%) | Factors Impacting AUTL price | AUTL will decline at least -1.74% in a week (0% probabilities). TIP(-82%) UNG(-39%) SHY(-35%) USO(-20%) BND(-19%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.74% (StdDev 3.48%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
Resistance Level | $4.3 | 5 Day Moving Average | $4.18(-3.59%) | 10 Day Moving Average | $4.32(-6.71%) | 20 Day Moving Average | $4.3(-6.28%) | To recent high | -13.9% | To recent low | 15% | Market Cap | $211m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |